Human Reproduction, Vol. 9, No. 4, pp. 638-642, 1994
© 1994 European Society of Human Reproduction and Embryology
other |
Accumulation of human chorionic gonadotrophin in the serum of patients during in-vitro fertilization treatment cycles with Pergonal
Department of Clinical Biochemistry Manchester M20 8LR, UK 2Assisted Reproduction Unit, Hope Hospital Salford M6 8HD, Manchester M20 8LR, UK 3Department of Chemical Pathology, Withington Hospital Manchester M20 8LR, UK
Correspondence: 1To whom correspondence should be addressed
We examined the possible contribution of human chorionic gonadotrophin (HCG) in Pergonal to the serum luteinizing hormone (LH)-like bioactivity in 10 patients (median age32 years, range 2838) with tubal infertility who were undergoing in-vitro fertilization (IVF), together with 19 controls (median age30 years, range 2143). IVF patients were treated with clomiphene (50 mg twice daily) over days 26 and Pergonal (150 IU i.m.) daily from day 5 until at least day 10. Serum LH was measured by fluoro-immunometric assay (I-LH) and in-vitro Leydig cell bioassay (B-LH). Serum HCG was measured by fluoro-immunometric assay. The data were analysed by paired two-tailed t-test, following logarithmic transformation. From days 15, there was an increase in serum B-LH (mean, 95% confidence intervals given in parentheses) from 8.3 (6.8, 10.2) IU/1 to 11.7 (9.8, 13.9) IU/1 [P= 0.004], and in serum I-LH from 4.5 (3.7, 5.4) IU/1 to 5.4 (4.6, 6.3) IU/1 [P= 0.002]. From days 58, there was a rise in B-LH to 16.6 (12.6, 21.9) IU/1 [P= 0.023]. The rise in I-LH to 6.3 (5.1, 7.8) IU/1 [P= 0.081] failed to reach significance. Furthermore, serum HCG was <<0.75 IU/1 until after Pergonal was administered on day 5, then rose to a plateau on day 8 at 1.2(0.8, 1.6) IU/1. Serum HCG in the controls remained <<0.75 IU/1 throughout. We conclude there is a disproportionate increase in serum B-LH compared to I-LH from days 58, corresponding with a rise in serum HCG and the commencement of treatment with Pergonal. The HCG in Pergonal may be contributing to an undesirable rise in serum LH-like bioactivity, which might reduce the success rate of IVF.
Key words: bioactivity/HCG/HMG/IVF/LH
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Filicori, G.E. Cognigni, P. Pocognoli, C. Tabarelli, D. Spettoli, S. Taraborrelli, and W. Ciampaglia Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration Hum. Reprod., August 1, 2002; 17(8): 2009 - 2015. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Filicori, G. E. Cognigni, S. Taraborrelli, D. Spettoli, W. Ciampaglia, C. Tabarelli de Fatis, P. Pocognoli, B. Cantelli, and S. Boschi Luteinzing Hormone Activity in Menotropins Optimizes Folliculogenesis and Treatment in Controlled Ovarian Stimulation J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 337 - 343. [Abstract] [Full Text] |
||||

